Potential age-at-exposure-related susceptibility for the following different CJD forms and exposures:

<p>(a) Age-susceptibility function for vCJD in the UK <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0109412#pone.0109412-Ghani1" target="_blank">[12]</a>, and results from <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0109412#pone-0109412-t001" target="_blank">Table 1</a> for risk of sCJD from age at first hospital discharge associated with a registered, main surgical procedure, at a lag of ≥20 years. (b) Reported estimated risks relating to 5- to 10-year age groups, after adjustment for dietary exposure to bovine material and average incubation period established at 12.6 years for variant CJD in the UK <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0109412#pone.0109412-Boelle1" target="_blank">[13]</a>, and plotted results from <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0109412#pone-0109412-t001" target="_blank">Table 1</a> for risk of sCJD from age at first hospital discharge associated with an etiologically reclassified <i>higher-risk</i> or <i>lower-risk</i> procedure, at a lag of ≥20 years. (c) Reported rate ratios of accidentally transmitted CJD (iCJD), for ever treatement vs never treatement with pituitary growth hormone (all treatments) at specific ages <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0109412#pone.0109412-Swerdlow1" target="_blank">[11]</a>. Reference: all other ages at treatment. (d) Reported rate ratios of accidentally transmitted CJD (iCJD) for ever treatment vs never treatment with pituitary growth hormone processed with the Hartree-modified Wilhelmi method (an hGH preparation associated with highest risk of iCJD among hGH-treated cohorts) at specific ages <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0109412#pone.0109412-Swerdlow1" target="_blank">[11]</a>. Reference: all other ages at treatment.</p

Associations for surgical procedures predating the time point of clinical onset in cases or the corresponding index date in controls by ≥20 years.

<p>Models 1 and 2, anatomic SP classification; models 3 and 4, etiologic SP classification. Other risk SPs encompass three reported etiologic SP categories, i.e., <i>lowest-risk</i>, <i>no-risk</i>, and <i>not reclassified</i><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0109412#pone.0109412-dePedroCuesta2" target="_blank">[7]</a>. Age subcategories <30, 30–39, and ≥40 years at first-registered surgery.</p>a<p>Subsidiary procedures' is a heterogeneous category that includes minor surgery (punctures, needle aspiration or biopsy, superficial incisions), other non-surgical, potentially invasive procedures, such as transluminal endoscopies (with or without biopsy), and, in a few instances in Denmark, blood transfusion.</p><p>SP-code distribution by body system groups in exposed cases.</p>b<p>n = 15. Female genital organs and obstetric SP, 7; Digestive system and spleen, 3; Other groups, 5.</p>c<p>n = 15. Female genital organs and obstetric SP, 8; Digestive system and spleen, 3, Other groups, 4.</p>d<p>n = 37. Female genital organs and obstetric SP, 18; Digestive system and spleen, 8; Peripheral vessels and lymphatic system, 5; Other groups, 6.</p>e<p>HR or LR SPs: acronym for <i>higher-risk</i> or <i>lower-risk</i> SPs <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0109412#pone.0109412-dePedroCuesta2" target="_blank">[7]</a>.</p><p>Associations for surgical procedures predating the time point of clinical onset in cases or the corresponding index date in controls by ≥20 years.</p